GlassScriptPhysician profile
Bryant Motykowski
NPI 1619438744
$5,489.56
in general payments reported to CMS, 2019-2025
20 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $2,315 · 2023: $2,062 · 2024: $98.88 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,312.90 | 2022-2023 | Pomalyst, Opdivo |
| Janssen Biotech, INC. | $766.75 | 2022-2023 | Tecvayli, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $715.36 | 2022-2023 | Enhertu, Lynparza, Tezspire |
| Genzyme Corporation | $420.75 | 2021-2023 | |
| Genentech USA, INC. | $292.80 | 2022-2023 | Lunsumio |
| Merck Sharp & Dohme LLC | $249.96 | 2023 | Lynparza, Keytruda |
| Amgen INC. | $223.23 | 2021-2023 | Evenity, Tezspire |
| Tempus Ai, INC | $190.64 | 2024-2025 | Xt Cdx |
| Celgene Corporation | $189.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.01 | 2022 | |
| G1 Therapeutics, INC. | $125.01 | 2021 | |
| Intercept Pharmaceuticals, INC. | $122.76 | 2021 | |
| Aveo Pharmaceuticals, INC. | $122.27 | 2021 | |
| Stemline Therapeutics INC. | $120.00 | 2023 | Orserdu |
| Daiichi Sankyo INC. | $117.95 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $92.91 | 2021 | |
| Beigene USA, INC. | $89.02 | 2022 | |
| Puma Biotechnology, INC. | $80.87 | 2022 | |
| Blueprint Medicines Corporation | $72.15 | 2023 | Ayvakit |
| Eisai INC. | $24.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Motykowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.